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Abstract
For a long time nucleic acid-based approaches directed towards controlling the propagation of Hepatitis C Virus (HCV) have
been considered to possess high potential. Towards this end, ribozymes (i.e. RNA enzymes) that specifically recognize and
subsequently catalyze the cleavage of their RNA substrate present an attractive molecular tool. Here, the unique properties
of a new generation of ribozymes are taken advantage of in order to develop an efficient and durable ribozyme-based
technology with which to target HCV (+) RNA strands. These ribozymes resulted from the coupling of a specific on/off
adaptor (SOFA) to the ribozyme domain derived from the Hepatitis Delta Virus (HDV). The former switches cleavage activity
‘‘on’’ solely in the presence of the desired RNA substrate, while the latter was the first catalytic RNA reported to function
naturally in human cells, specifically in hepatocytes. In order to maximize the chances for success, a step-by-step approach
was used for both the design and the selection of the ribozymes. This approach included the use of both bioinformatics and
biochemical methods for the identification of the sites possessing the greatest potential for targeting, and the subsequent
in vitro testing of the cleavage activities of the corresponding SOFA-HDV ribozymes. These efforts led to a significant
improvement in the ribozymes’ designs. The ability of the resulting SOFA-HDV ribozymes to inhibit HCV replication was
further examined using a luciferase-based replicon. Although some of the ribozymes exhibited high levels of cleavage
activity in vitro, none appears to be a potential long term inhibitor in cellulo. Analysis of recent discoveries in the cellular
biology of HCV might explain this failure, as well as provide some ideas on the potential limits of using nucleic acid-based
drugs to control the propagation of HCV. Finally, the above conclusions received support from experiments performed
using a collection of SOFA-HDV ribozymes directed against HCV (2) strands.
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Introduction
Hepatitis C Virus (HCV) is the major worldwide cause of both
blood transfusion-associated and sporadic non-A, non-B hepatitis.
Estimates place the number of HCV-infected individuals world-
wide at 170 million, representing nearly 3% of the world’s
population [1,2]. In 20–30% of these patients the HCV infection is
acute and the virus is naturally cleared. The majority (70–80%)
remain chronically infected, leading to various clinical outcomes
including an asymptomatic carrier state with normal or almost
normal liver functions, acute hepatitis and, about 50% of the time,
chronic hepatitis. Today, chronic HCV infections can only be
treated with pegylated interferon-a (IFN-a) [1,2]. Unfortunately,
about 70% of compliant patients experience a relapse, and only
25% maintain low serum alanine aminotransferase levels.
Although a combination therapy including the purine nucleoside
analogue ribavirin improves the rate of success, only 40% of
patients infected with HCV achieve a sustained response.
Moreover, in clinical practice many patients do not qualify for
IFN-a therapy for several reasons. Hence, only a minority of
patients with chronic hepatitis C can be successfully treated and,
consequently, projections indicate that the mortality rate from
hepatocellular carcinoma associated with chronic hepatitis C will
further increase in the next 15–20 years [1,3]. Clearly, it is an
urgent mission to search for innovative strategies with which to
treat/cure HCV infected patients.
HCV, a member of the Flaviviridae family, is an enveloped virus
with a plus-stranded RNA genome ,9,6 kb in length (Figure 1A)
[4]. Six major genotypes and more than 50 minor subtypes have
be distinguished. The high replicative activity of the virus, together
with the lack of a proofreading function of the viral RNA
polymerase, provides the basis for the significant genetic variability
of HCV. This genome carries a single long open reading frame
(ORF) which encodes a polyprotein of ,3,010 amino acids that is
subsequently cleaved both co- and post-translationally into the
mature viral proteins. The ORF is flanked by structured 59 and 39
untranslated regions (UTRs) that are important for both the
translation of the polyprotein and the replication of the genome.
For example, the 59 UTR is highly conserved among different
HCV isolates and contains an internal ribosomal entry site (IRES)
essential for the cap-independent translation of the viral RNA [5].
Several antiviral strategies are being explored for the treatment
of HCV infections [6,7]. For example, antiviral inhibitors that
block essential viral enzymes, such as the NS3–4 protease or the
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that are currently at different stages of development [8–10].
Moreover, gene-inactivation approaches, including the use of
antisense oligonucleotides and, more recently, RNA interference
(RNAi), also show some promise in terms of being able to inhibit
both HCV replication and gene expression in experimental
systems [11–15]. However, the RNAi approach has been shown
to trigger an immunological response, which poses an important
limitation in terms of further therapeutical applications [16–18].
Ribozymes (Rz), RNA molecules that catalyze the cleavage of
RNA substrates, are an interesting alternative to the RNAi
approach to gene inactivation. Both ribozymes and deoxyribo-
zymes have been demonstrated to block both viral replication and
gene expression in experimental systems both in vitro and in
cellulo [19–22].
Among the different ribozymes, Hepatitis Delta Virus ribozyme
(HDV Rz) was for a long time the sole example derived from an
RNA species naturally found in human cells (i.e. the infected
hepatocytes) [23,24]. As a result, HDV Rz offers several unique
properties as a potential tool, including the natural ability to
function in the presence of human proteins and at the
physiological magnesium concentration (1 mM Mg
2+). Further-
more, HDV Rz has a long half-life, regardless of both the cell line
tested and the means of transfection used [23]. Thus, HDV Rz
appears to be well adapted to the human cell environment and is
therefore an interesting potential candidate for the development of
a gene-inactivation system. This potential has subsequently been
demonstrated in vitro as well as in cellulo by the use of HDV
ribozyme to cleave various natural mRNA [24–28]. The HDV Rz
folds into a model pseudoknot secondary structure in which
substrate recognition is based solely on the formation of the P1
stem, a stem that involves only 7 base pairs (bp) (Figure 1B).
Recently, molecular engineering has led to the development of a
novel target-dependent riboswitch that increases HDV Rz fidelity
[29]. This latter ribozyme possesses a specific on/off adapter
(SOFA) that switches the cleavage activity from off (i.e. like a
‘‘safety lock’’) to on solely in the presence of the desired RNA
substrate. The SOFA module is composed of three domains: a
blocker, a biosensor and a stabilizer [30]. The blocker sequence
inhibits the cleavage activity of the ribozyme by binding, in cis, the
P1 domain of the ribozyme portion. This provides an inactive
SOFA-HDV ribozyme, i.e. off conformation. The biosensor must
bind its complementary sequence on the substrate in order to
unlock the SOFA module, thereby permitting the folding of the
catalytic core into the on conformation. Both the blocker and the
biosensor have been shown to increase the substrate specificity of
the ribozyme’s cleavage by several orders of magnitude compared
with the wildtype HDV ribozyme [29]. This is due mainly to the
addition of the biosensor domain that increases the binding
strength of the HDV ribozyme to its target but it is also due to the
fact that the blocker domain interacts with the P1 domain and
decreases its binding capacity. It is important to note that the
sequences of the substrate binding both the P1 and the biosensor
domains are not contiguous, but rather separated by a small region
named spacer that usually varies from 4 to 7 nt for optimal design
[30]. Finally, the presence of the stabilizer (i.e. the stem that brings
together both the 59 and 39 extremities), which has no effect on the
cleavage activity, stabilizes the SOFA-HDV ribozymes in vivo
against ribonucleases [29]. This new development provides a
highly specific and improved HDV-based molecular tool that
displays significant potential for application in the fields of both
functional genomics and gene therapy.
In the present work, the unique properties of the HDV Rz that
are improved by the presence of the SOFA adapter are used in
order to attempt to develop a ribozyme-based technology with
which to target HCV. Sites with greatest potential for targeting in
the HCV strands of both polarities were identified, followed by a
screen to find the most active SOFA-HDV ribozymes.
Results
Identification of Potential Target Sites in the HCV (+)
Strand RNA
Since HCV is known to exhibit several genotypes and many
subgenotypes, the identification of the most highly conserved
sequences within its genome is critical to the development of
nucleic acid based drugs that possess the ability to specifically bind
to most, if not all, of the sequence variants. Consequently, only the
first 341 nucleotides (nt) of the HCV (+) strand that correspond to
the 59 UTR, a region that is known to be highly conserved, were
considered for targeting. Moreover, only the HCV (+) strand was
analyzed because it has been reported to be significantly more
abundant then its (2) counterpart [31,32].
The initial step in developing a ribozyme capable of specifically
cleaving the HCV (+) RNA was the identification of the sites most
accessible for targeting. Sites located in single-stranded regions
should exhibit a higher ribozyme binding potential than those
Figure 1. Schematic representations of both the HCV genome
and the SOFA-HDV ribozyme. (A) HCV genomic RNA organization
including the structured 59 and 39 UTRs. (B) Secondary structure of both
the off (left) and on (right) conformations of the SOFA-HDV ribozyme.
The SOFA module is highlighted in grey. The P1 domain (ribozyme
binding domain), the biosensor, the blocker and the stabilizer domain
are indicated blue, green, red and brown, respectively. The spacer
region separating the substrate’ sequences binding by the P1 and
biosensor domains of the ribozyme is indicated in grey. The arrow
indicates the cleavage site. All structures have been previously
described [29,30].
doi:10.1371/journal.pone.0009627.g001
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issue, a bioinformatics approach was initially used to identify the
most accessible sites (see Figure 2). Using the RNA folding
software RNA Structure 3.7 [34], a series of potential secondary
structures that can be formed by the 341-nt RNA sequence were
obtained. The twenty most stable structures were then analyzed
using the OligoWalk software, which provides, in terms of energy,
the degree of accessibility of short sequences along the different
structures [34]. A window size of 7 nt, corresponding to the
binding domain of the HDV Rz, was used (i.e. the P1 stem). Using
a cut-off value of smaller than 212 kcal/mol for the predicted
binding constant of the substrate to the ribozyme, this analysis
identified 55 potentially accessible sites.
The resulting sites were then further analyzed to see if they
fulfilled the criteria essential for efficient HDV Rz cleavage.
Specifically, the first nucleotide downstream of the cleavage site
(position +1) has to be a guanosine in order to allow formation of a
critical GU Wobble bp with the ribozyme (position +1, Figure 1B),
and the nucleotide upstream of the cleavage site should not be a
guanosine (position 21, Figure 1B). Application of these
constraints shortened the list to 15 potential target sites
(Figure 2). Next, biochemical assays were performed in order to
validate the bioinformatic predictions. Specifcally, RNase H
hydrolysis assays were performed in vitro using 7-nt oligonucle-
otides corresponding to the binding domain of the HDV Rz and a
575-nt HCV-derived RNA species corresponding to the 59 region
of the genome. RNase H specifically cleaves the RNA half of an
RNA-DNA duplex. In this analysis, the most accessible sites, that
is, those that bind the oligonucleotides, should be cleaved by the
RNAse H. Five’-end-labeled HCV-derived transcripts were pre-
incubated with the oligonucleotides prior to being incubated with
RNase H and analyzed samples. Figure 2 shows an example of
autoradiogram performed with a 5% polyacrylamide gel. The time
of migration used provides a resolution suitable for the analysis of
the sites located between positions 188 to 313. In this example, 5
out of the 6 oligonucleotides generated specific hydrolysis
products, although at different levels. It is important to note that
because the sites 233 and 311 share the same 7 nt sequence, one
oligonucleotide permitted the evaluation at both sites. Efficient
hydrolysis was detected at position 311 while only a faith band at
position 233. Several electrophoresis with various migration times
were performed in order to evaluate the 14 different oligonucle-
otides. These experiments permitted the validation of 8 potential
sites and data was compiled at Table 1. These 8 sites are located
throughout the 59 UTR, albeit with a predominance within the
region from 299 to 318 in which four of the eight are located.
Figure 2. Schematic representation of the 3-step procedure
used for the identification of the sites possessing the greatest
targeting potential in the HCV 59-UTR. Step 1 involved a
bioinformatic analysis that included both the prediction of the
secondary structure and the identification of the 7 nt streches most
likely to be bound by the ribozyme’s P1 region using both the RNA
structure 3.7 and Oligowalk softwares. Step 2 involved the selection of
the sequences that fulfill the HDV ribozyme requirements. Step 3
involved the RNase H hydrolysis assay. The autoradiogram shown
corresponds to a typical 5% polyacrylamide gel performed for the
analysis of 6 potential sites. The positions of proposed cleavage sites are
identified at the top of the gel. The negative control performed in the
absence of any oligonucleotide is indicated by the letter C.
doi:10.1371/journal.pone.0009627.g002
Table 1. Compilation of the data from the RNase H hydrolysis
of HCV (+) RNA.
Cleavage
positions Oligonucleotide sequences RNase H hydrolysis
15 CGCCCCC 2
110 TGGAGGC 2
117 GGGGTCC +
176 TCCTGGC 2
184 CCCGGTC 2
188 AGGACCC 2
217 TCCAGGC 2
229 CACGCCC +
233 GGGGCAC +
235 CGGGGGC 2
266 GCGACCC +
299 AGCACCC +
311 GGGGCAC +
313 CCGGGGC +
318 ACCTCCC +
doi:10.1371/journal.pone.0009627.t001
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subsequent step. The analysis of the 59 to 39 distribution of the
selected sites revealed a bias that lowered representation in the
region spanning positions 1 to 200. Only the site at position 117
was retrieved within this region. In order to obtain more sites in
the region spanning positions 1 to 200, 8 other sites were selected.
The selection for these new sites was based on the presence of a
high level of sequence conservation as well as their potential
accessibility according to the reported crystal structure of the HCV
IRES [5] (see Table 2). Together, these analyses provided a
collection of 17 potential sites for targeting in the HCV (+) strands.
Designing of the SOFA-HDV Ribozymes
The various selected target sequences of the HDV ribozymes
were all highly conserved among the major HCV genotypes (data
not shown), a prerequisite for the development of a viable HDV
Rz-based therapeutical approach. Preliminary sequence homology
searches between the HDV Rz and a bank of human transcripts
revealed that the ribozymes could potentially target several human
transcripts (version 35.1 of the human genome). These potential
off-target effects resulted from the limited size of the recognition
domain present in the original HDV Rz (only 7 nt). It has been
estimated that a minimum sequence of 13–14 base pairing
nucleotides is required for the specific targeting of an unique RNA
species in the human transcriptome [35]. In order to improve the
substrate specificity of each ribozyme, a SOFA module was
designed for each (see the description of the SOFA in the
Introduction section and in reference [29]). In each case the
biosensor sequences added are presented in Table 2. The
sequence located between the ribozyme and the biosensor binding
domains on the HCV target, the so-called spacer domain, was
always kept between 4 and 7 nt in length as this length has been
shown to be optimal [30], except in the cases SOFA-HDV-Rz170
and -Rz188. The former includes a spacer of 11 nt, while the latter
possesses one of 10 nt, and both were required in order to improve
the biosensor binding site’s conservation level. As a result, the
designed SOFA-HDV ribozymes should target only the desired
sequence’s region, and should therefore be specific enough to
target only HCV. Moreover, the addition of the biosensor
sequence of the SOFA domain permits the differentiation between
the recognition sites of the SOFA-HDV-Rz233 and –Rz311
ribozyme even though they share the same sequence for the P1
region of the ribozyme domain.
In Vitro Cleavage Assay of the Potential SOFA-HDV
Ribozymes
The next step was the synthesis of a collection of SOFA-HDV
ribozymes and the identification of those that demonstrate the
highest levels of cleavage activity in vitro. The ability of each
SOFA-HDV ribozyme to cleave 59-radiolabeled 575-nt HCV
RNA was tested under single-turnover conditions ([Rz]&[S]). A
typical example is illustrated in Figure 3. The time of migration
used for this specific electrophoresis was suitable for the resolution
of the sites located in the 59end of the HCV IRES (positions 1 to
200). In this example, the SOFA-HDV-Rz21, -Rz60 and -Rz68
ribozymes exhibited high levels of cleavage. All others cleaved less
efficiently. Five ribozymes exhibited cleavage levels .20%, a level
that we considered relatively high for the cleavage of a long and
highly structured RNA species. Several electrophoresis using
different migration time were performed to monitor the cleavage
level at the various positions (raw data not shown) and the data
were compiled at Table 2. Overall, 7 out of 17 SOFA-HDV
ribozymes exhibited significant cleavage of the substrate (i.e.
cleavage percentage .10%; Table 2). Clearly, these results suggest
that the time invested in identifying the most accessible sites was
productive, as without it this number would certainly have been
smaller. The 5 SOFA-HDV ribozymes that exhibited a cleavage
Table 2. Compilation of the in vitro cleavage of HCV (+)
strand by the SOFA-HDV ribozyme data.
Cleavage
positions
Rz P1
sequences
Rz Biosensor
sequences Cleavage %
117 GGGGUCU UGGCUCUCCCGG 0261
188 AGGACCU AUUGAGCGGGUU 0261
229 CACGCCU UAGCAGUCUCGC 0761
233 GGGGCAU CGGCUAGCAGUC 0161
266 GCGACCU GUACCACAAGGC 1061
299 AGCACCU CUCCCGGGGCAC 1363
311 GGGGCAU GGUCUACGAGAC 0761
313 CCGGGGU ACGGUCUACGAG 3362
318 ACCUCCU GGUGCACGGUCU 2961
21 GAGUGUU GGGAGUGAUCUA 2161
60 UGAAGAU GCUAGACGCUUU 3963
68 UUUCUGU ACGCCAUGGCUA 3561
82 CCAUGGU CGACACUCAUAC 0461
135 AUGGCUU CGGUUCCGCAGA 0761
143 AGACCAU GUACUCACCGGU 0261
170 CAAUUCU AAGAAAGGACCC 0161
200 UUGAUCU UCCAGGCAUUGA 0461
The sequences for each SOFA-HDV Rz corresponding to their P1 and biosensor
recognition domains are listed. The upper section includes the SOFA-HDV Rz
targetable sites as identified by bioinformatic and biochemical procedures,
while the lower section includes those based on the reported secondary and
crystal structures.
doi:10.1371/journal.pone.0009627.t002
Figure 3. Typical autoradiogram of an 8% polyacrylamide gel
performed in order to analyze SOFA-HDV ribozyme cleavage in
vitro. The experiments were performed using 59-end-labeled HCV
transcripts in the presence of an excess of SOFA-HDV ribozyme. The
SOFA-HDV ribozymes are identified at the top of the gel. The negative
control performed in the absence of ribozyme is indicated by the letter
C. The positions of the xylene cyanol (XC) and bromophenol blue (BPB)
marker dyes are indicated.
doi:10.1371/journal.pone.0009627.g003
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expected SOFA-HDV-Rz188 that was the negative control. The
other 12 SOFA-HDV ribozymes were conserved for the
subsequent step.
Evaluation of the SOFA-HDV Ribozymes Cleaving the
HCV (+) Strand In Cellulo
The potential abilites of all SOFA-HDV ribozymes to inhibit an
HCV replicon were tested. Prior to this experiment, the ribozymes
were cloned adjacent to a tRNA
Val in modified pLenti plasmids.
The resulting plasmids were used to produce lentivirus which in
turn were used to transduce Huh-7 cells (see Materials and
Methods). The use of the tRNA
Val as both promoter and leader
sequence has previously been proven to be successful for both the
production and the localization of HDV ribozymes [26]. It permits
the production of a large amount of the chimeric RNA by the host
RNA pol III. In addition, it is well known that the tRNA motif
directs the expressed ribozyme to the cytoplasm, where it
hybridizes to the targeted mRNA [36,37]. The expression of all
chimeric tRNA
Val:SOFA-HDV ribozymes was confirmed at the
time of the replicon inhibition assay (i.e. 48 h post transduction,
data not shown). Results from preliminary expression experiments
showed that 48 to 72 h post transfection was the optimal window
for the expression of the ribozymes. The excess of chimeric
tRNA
Val:SOFA-HDV ribozymes over targeted HCV strands
remained undetermined. However, detection of tRNA
Val:SOFA-
HDV ribozymes was performed by Northern blot hybridizations
and confirmed their relatively large abundance while HCV strand
were barely detectable using the same technique (data not shown).
These results support the notion that the ribozymes were in excess
compared to the HCV substrate, although this does not constitute
direct evidence.
It is important to note that during an experiment neither G-418
nor antibiotic were used in order to reduce interference with cell
transduction as well as to avoid the positive selection of HCV
replicon containing cells while measuring the effect of the SOFA-
HDV ribozymes. The Huh-7 cells containing the subgenomic
biscistronic replicon Luc-ubi-neo-ET, which includes the firefly
luciferase ORF that provides a quick enzymatic assay for drug
screening, was used (Figure 4A) [38]. Similar replicon systems
were used in many other studies in order to screen various nucleic
acid-based approaches including siRNA [e.g. 39–43]. A colori-
metric assay was performed for normalization purposes by
considering the total protein concentration. Each SOFA-HDV
ribozyme tested was compared to an irrelevant one possessing a
recognition sequence that should not be able to interact with either
the HCV RNA, nor with any human mRNA (as determined by a
homology search). The latter SOFA-HDV ribozyme was originally
engineered to target the hepatitis B virus (SOFA-HDV-RzHBV)
[29]. Its use permitted determination of the relative percentage of
luciferase detected in the presence of each SOFA-HDV ribozyme,
as compared to that observed in the presence of the irrelevant one
which was arbitrarily set at a luciferase/protein ratio of 100%. At
least two or three biological replicates were performed for all
ribozymes, and typical results are illustrated in Figure 4B. Simple
cell exposition to polybrene, the transduction reagent, or even the
expression of the tRNA
Val alone, led to a variation of +/220%
(data not shown). Consequently, it was decided that a ribozyme
must decrease the luciferase/protein ratio by at least 20% in order
for it to be considered a significant inhibition of replication. Using
this criteria, 7 SOFA-HDV ribozymes were rejected (i.e. SOFA-
HDV-Rz21, -Rz60, -Rz68, -Rz82, -Rz135, -Rz200, and -Rz229).
One ribozyme exhibited intermediate inhibition level at 25% (i.e.
SOFA-HDV-Rz266). Most importantly, 4 ribozymes exhibited
cleavage activities that led to .30% reductions in the luciferase/
protein ratio: the SOFA-HDV-Rz311, -Rz313 and -Rz318
reduced the level between 30 and 40%, while SOFA-HDV-
Rz299 caused even more significant reduction (i.e. a 42%
luciferase/protein).
The experiment was repeated several times, and always
produced similar results and experimental variation when the
same lentivirus preparation was used, while use of different viral
preparations increased the experimental variation (data not
shown). The use of different lentivirus concentrations did not
result in improved inhibition of the replicon. Similarly,
prolonged exposition of the cells to the lentiviruses did not lead
Figure 4. Analysis of the inhibition of the HCV replicon by
SOFA-HDV ribozymes. (A) Schematic representation of the HCV
replicon used (described previously [38]). (B) and (C). Histograms of the
relative luciferase activities detected for the HCV (+) and (2) strands,
respectively. Luciferase activity was detected in the presence of all
SOFA-HDV ribozymes tested, and was reported relative to that
determined for an irrelevant SOFA-HDV ribozyme whose level was
arbitrarily set at 100%. The latter SOFA-HDV ribozyme was designed to
target the hepatitis B virus and does not possess the sequences
required in order to recognize the HCV strands of either the (+) or the
(2) polarity. The characterization of this SOFA-HDV ribozyme was
previously reported [29].
doi:10.1371/journal.pone.0009627.g004
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summary, some SOFA-HDV ribozymes exhibited sufficiently
high cleavage levels of the IRES that they significantly reduced
the luciferase activity; however, the observed level of replicon
inhibition was never high enough to warrant further develop-
ment of the SOFA-HDV ribozyme as an antiviral drug against
HCV. In order words, although the new generation of
ribozyme, specifically the SOFA-HDV ribozyme, provides a
highly specific and improved tool with significant potential for
practical application, its potential for controlling HCV replica-
tion appears limited.
Designing SOFA-HDV Ribozymes That Cleave the HCV
(2) Strand
One possible explanation for the limited inhibitory effect of the
SOFA-HDV ribozyme against HCV (+) strands might be the fact
that the replication complex is compartmentalized by a lipid
bilayer membrane [32,44–45]. This localization considerably
reduces the accessibility of the HCV RNA (+) strand to the
SOFA-HDV ribozyme during replication. In fact, the action of the
ribozymes may take place mainly, if not exclusively, during the
translation of the (+) strand that encodes the polyprotein. If this is
indeed the case, it should be almost impossible to target the HCV
(2) strand in cellulo because they are non-coding, and, therefore,
are not accessible during the translation step. In order to verify this
hypothesis, SOFA-HDV ribozymes specifically targeting the 39-
end of the HCV (2) strand that is the counterpart of the 59 UTR
found in the (+) strand were designed and tested for cleavage
activity both in vitro and in cellulo.
Instead of applying a complex design strategy, HCV sequence
alignment was used to identify both highly conserved sequences in
the HCV genome and potential sites for HDV ribozyme cleavage
(i.e. those harboring the sequence H21G+1; with H being C, U or
A). The 39-end region of the HCV (2) strand was shown to fold
into a secondary structure, but not one as stable as the IRES
adopted by the HCV (+) polarity strand [46]. Application of this
criteria led to the identification of 14 potential sites, all of which
were located in the last 341 nt of the HCV (2) strand (see Table 3).
The cleavage activities of all of the corresponding SOFA-HDV
ribozymes were assayed in vitro using a 575-nt transcript derived
from the HCV (2) strand that was the counterpart of the one used
for the (+) polarity above. All SOFA-HDV ribozymes exhibited
cleavage (.1%, Table 3). Three ribozymes exhibited a limited
level of ,10%, seven exhibited a significant level of between 10
and 20% and four exhibited a cleavage level over 20%.
Specifically, SOFA-HDV-Rz166
2, -Rz327
2, -Rz304
2 and -
Rz293
2 exhibited cleavage activities of 24%, 43%, 70% and
85%, respectively (see Table 3). Observation of such significant
levels of cleavage for the HCV (2) strand provides a good
indication that it is less stable than its (+) counterpart.
T h ec l e a v a g eo ft h eH C V( 2)s t r a n db ya l lo ft h e s eS O F A -
HDV ribozymes was then accessed using both the replicon and
the lentivirus systems as described above. Only 3 SOFA-HDV
ribozymes out of the 14 reduced the level of luciferase activity of
approximately 10%. Specifically, SOFA-HDV-Rz317
2,-
Rz327
2 and -Rz334
2 showed reductions of 10%, 10% and
8%, respectively, all just below the cut-off previously established
for considering a ribozyme as being active. In other words, even
the ribozymes that possess an outstanding cleavage activity in
vitro did not efficiently cleave the HCV (2) in cellulo. Together,
these data support the hypothesis that the HCV (2)s t r a n d
a p p e a r st ob ei n a c c e s s i b l ef o rc l e a v a g eb yt h eS O F A - H D V
ribozymes.
Discussion
Designing SOFA-HDV Ribozymes
We report here the first extensive design of SOFA-HDV
ribozymes directed against two distinct RNA targets (considering
both the (+) and (2) HCV strands as distinct RNA molecules).
Previous studies directed towards the development of a gene-
inactivation system based on this nucleic acid approach always
included a minimal number of ribozymes (i.e. only one to five
ribozymes per target [25,28,29]). In the present study, a total of 31
SOFA-HDV ribozymes targeting the HCV strands were designed
and their cleavage activities accessed in vitro. Seventeen of these
SOFA-HDV ribozymes targeted the HCV (+) strand, while
fourteen targeted the (2) counterpart. Although not a very large
collection of ribozymes, this number should be sufficient to
provide some information on the features that must be considered
in the design step. In this report the analysis was limited to the data
from in vitro cleavages because inclusion of the in cellulo results
implicates too many other important features, including several
that remain to be identified.
In order to facilitate the analysis, the cleavage positions of all
SOFA-HDV ribozymes tested in vitro are illustrated on the
proposed secondary structures of both the (+) and (2) HCV
strands (Figure 5). Ribozymes that showed either limited or no
cleavage activity are in red, while those exhibiting moderate or
relatively high levels of cleavage activity are in yellow and green,
respectively.
The structure of a target is obviously an important feature to
consider when targeting an RNA molecule in trans. The formation
of double-stranded RNA within the target region can compete
with any ribozyme binding that involves unfavourable intramo-
lecular base pairings. This study presents an elegant example of
this situation. In the case of the HCV (+) strand, only 7 out of the
17 SOFA-HDV ribozymes exhibited cleavage activities of greater
than 10% (Figure 5A). Six of these ribozymes targeted sites located
Table 3. Compilation of the in vitro cleavage of the HCV (2)
strand by SOFA-HDV ribozyme data.
Cleavage
positions
Rz P1
sequences
Rz Biosensor
sequences Cleavage %
130 CCCUCCU CAGCCUCCAGG 0463
148 AGUGGUU CCUCCCGGGAGA 1862
151 GGUCUGU CCCGGGAGAGCC 1463
157 CGGAACU AGAGCCAUAGUG 0463
166 UGAGUAU GUGGUCUGCGGA 2465
169 GUACACU GUCUGCGGAACC 1761
255 GCUAGCU GCGUGCCCCCGC 1667
293 UACUGCU GCGAAAGGCCUU 8566
304 AGGGUGU UUGUGGUACUGC 7067
317 GUGCCCU UGAUAGGGUGCU 1265
325 GGAGGUU UGCUUGCGAGUG 1463
327 AGGUCUU CUUGCGAGUGCC 4365
334 GUAGACU GUGCCCCGGGAG 1565
338 ACCGUGU CCCGGGAGGUCU 0963
The sequences for each SOFA-HDV Rz corresponding to their P1 and biosensor
recognition domains are listed. Nucleotide positions are numbered from 39 to
59 in order to facilitate concordance with the data obtained for the HCV (+)
strand.
doi:10.1371/journal.pone.0009627.t003
Ribozyme Targeting HCV
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9627either side of the highly structured IRES motif. Specifically, 3
SOFA-HDV ribozymes cleaved site before position 68, and 3 after
position 299. Conversely, the corresponding region of the HCV
(2) strand appears to fold into a less stable secondary structure
[46], resulting in 11 out of 14 SOFA-HDV ribozymes that
exhibited cleavage activities of over 10% cleaving in this region
(Figure 5B). The higher accessibility of the HCV (2) strand, as
compared to the (+) strand, also received support from the
discovery of two ribozymes that exhibited outstanding cleavage
levels when the length of target is taken into consideration (i.e.
SOFA-HDV-Rz293
2 and -Rz304
2).
The previous elucidation of the secondary structure was of great
help in designing the ribozymes directed against both strands. In
the case of the HCV (+) strand, the use of bioinformatics coupled
to validation by the RNase H hydrolysis was not really more
productive, in terms of the number of SOFA-HDV ribozymes that
exhibited significant cleavage activity, that was simple analysis of
the secondary structure (i.e. 4 and 3 SOFA-HDV ribozymes out of
8 in each case, respectively). However, it is important to remember
that the computer-assisted approach coupled to the biochemical
validation was performed on the original HDV Rz and only then
was the SOFA motif added. It should be noticed that it would be
irrelevant to perform RNAse H assays using long oligonucleotides
including the complementary sequence for the P1, the spacer and
the biosensor sequences. In that case the spacers would also be
hybridized favoring significantly the formation of the duplexes,
therefore introducing an important bias. Alternatively one might
imagine using two distinct oligonuleotides at the same time in the
RNase H assay (one for the P1 domain and the other for the
biosensor domain). In the later case, the resolution of the
electrophoresis would not be sufficient to allow distinction between
the binding of each oligonucleotide to the target. However, it has
previously been reported that the addition of the SOFA motif
reduces the importance of the accessibility hurdle [30]. Most likely
the presence of the biosensor domain that forms 11–12 base pairs
with the substrate contributes significantly, certainly in terms of
binding energy. It is easy to imagine that the subsequent binding of
the biosensor and the ribozyme’s P1 region to the substrate might
occur in a cooperative manner. Finally, we noted that the more
accessible the complementary sequence of the biosensor (i.e. the
more it is located in a single-stranded region), the more efficient
the resulting SOFA-HDV ribozyme tended to be. However, this is
not a simple question of adding the base pairs involved in the
formation of both the P1 and biosensor domains. For that reason it
is complex to consider it during the in silico step of the SOFA-
HDV ribozyme’ design. There are many factors that influence the
binding of a ribozyme to a target that are not trivial to identify. For
example there is all the tertiary structure of the ribozyme by itself
that will influence the result, which cannot be taken into account
and, therefore, may influence the accuracy of the predictions and
contributes to some discrepancies.
Observation of the correlation between the sequence compo-
sition of the biosensor and the P1 strand of the ribozyme domain,
as well as of their binding sequences within the substrate, with the
cleavage efficiency prompts several conclusions. With the
exception of sequences rich in adenosine and uridine in either of
these two domains, these analyses did not reveal any bias towards
higher cleavage levels. Moreover, the presence of the biosensor
domain seems to reduce the importance of the composition of the
P1 domain. Previously reported analyses of HDV ribozyme
Figure 5. Analysis of the cleavage activity of the SOFA-HDV
ribozyme collections. (A) and (B). The cleavage activity levels
observed in vitro are illustrated on the proposed secondary
structures of both the HCV (+)a n d( 2) strands, respectively. The
secondary structures shown are as previously reported [13,40]. The
SOFA-HDV ribozymes exhibiting either no, or relatively low cleavage
activities (,10%), are indicated in red. Those exhibiting moderate
cleavage activities (between 10% and 20%) are indicated in yellow,
while those exhibiting relatively high cleavage activities (.20%) are
indicated in green. The arrows indicate the proposed cleavage
position of each SOFA-HDV ribozyme.
doi:10.1371/journal.pone.0009627.g005
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identity of the base pairs involving the pairing of substrate position
+4 with the ribozyme significantly influenced the activity level
[47]. For example, the presence of a guanosine residue in the
substrate that base paired with a cytosine in the ribozyme resulted
in the formation of an unproductive ribozyme-substrate complex.
These nucleotides, located in the middle of the P1 stem, have been
proposed to be essential for both substrate binding and the
subsequent steps in the cleavage pathway [47,48]. The fact that
both the SOFA-HDV-Rz68 targeting the HCV (+) strand, and -
Rz169
2 targeting the HCV (2) strand, each of which possesses a
cytosine in this position and exhibits a relatively high level of
cleavage activity, suggests that the requirements for the efficient
HDV ribozyme targeting of small substrates may differ from those
of the SOFA-HDV ribozyme targeting long RNA molecules. Even
so, the observed substrate specificity preferences found for
positions 21t o24 adjacent to the cleavage site using a small
substrate agree in part with the results observed for the collection
of SOFA-HDV ribozymes targeting the HCV strands. Previously,
a collection of small substrates possessing both single and multiple
mutations in positions 21t o24 was studied [49]. Some of these
substrates were found to be uncleavable, while others demonstrat-
ed almost two orders of magnitude of difference, in terms of
relative specificity, between the least and the most efficiently
cleaved substrates. The nucleotides located at each of these four
positions contribute differently to the ability of a substrate to be
cleaved [50]. The optimal sequence for positions 24t o21 was
determined to be 24YHRH21 (where Y indicates C or U; H
indicates A, C or U; and R indicates A or G [49]). Even if this
portion of the substrate is not part of the recognition domain (i.e.
the base-pairing domain), it has been proposed to play a crucial
role as an external determinant of the ability of a substrate to be
cleaved in addition to potentially imposing steric hindrances that
limit the cleavage activity. Several analyses were performed in
order to verify whether or not the cleavage activity of SOFA-HDV
ribozymes targeting HCV obeyed the same specificity require-
ments (raw data not shown). The identities of the bases located in
positions 21 and 22 appeared to significantly influence the
cleavage level observed. The presence of two consecutive
pyrimidines in these positions appears to be detrimental, although
to varying degrees. In terms of positions 23 and 24, the
nucleotides identities were less important, similar to what is
observed for small substrates.
In brief, the cleavage site of a substrate for SOFA-HDV
ribozyme should harbor a guanosine in position +1, no guanosine
is position 21, should be in agreement with the previously
determined preferable nucleotides in positions 21t o22, and, as
much as possible, should be accessible for binding. However, even
if in vitro experiments suggest the potential for success, there is no
guarantee that this will be the case in vivo. Moreover, there is
some, but not a perfect, correlation between the level of cleavage
observed in vitro with one detected in vivo. For example, SOFA-
HDV-Rz60 exhibited the best cleavage activity of the HCV (+)
strand in vitro but it was not the case in cellulo (i.e. 39% in vitro
compared to only 5% in cellulo; see Table 2 and Figure 4).
Similarly, the best cutter of the HCV (2) strand in vitro was not
the one that exhibited the higher level of cleavage in cellulo (i.e.
SOFA-HDV-Rz293
2 exhibited 85% of cleavage in vitro while it
was no inhibiting in cellulo). The opposite solution was also
observed. For exemple, the SOFA-HDV-Rz299 exhibited only
13% of cleavage in vitro but was the best one in cellulo with a 42%
of reduction. There are several parameters in cellulo that may
influence significantly the cleavage level and are not occurring in
vitro or taken into consideration during the design of the SOFA-
HDV ribozyme. Some parameters are related to the target (e.g.
the presence of interacting proteins either masking cleavage site or
modifying the structure of the substrate) while others are related to
the ribozyme by itself (i.e. the turnover and half-life of each
ribozymes may differed), to name only these examples. Clearly,
this is a complex problem and there is not a simple solution.
The SOFA-HDV Ribozymes May Be of Limited Interest for
HCV Treatment
This report shows that targeting the HCV replicon system using
SOFA-HDV ribozymes was not really productive, even when
great attention was devoted towards optimizing their design. The
in cellulo experiments were repeated several times using different
conditions, including the use of various lentivirus preparations,
transfection with the ribozyme and use of other HCV IRES-
mediated translation systems, to name only a few examples. Even
though inhibition of HCV replication was observed, it was only at
a relatively limited level. The suitable inhibition level required for
further development of a therapeutical approach is at least 80%
inhibition. Anything less would likely not lead to viral clearance.
Therefore, none of the SOFA-HDV ribozymes examined
appeared to be a potential candidate for further development in
HCV treatment.
One potential explanation for the limited cleavage activity
might be the bicistronic replicon system used to screen the
ribozyme in cellulo, although it has been used successfully in many
studies [38–43]. It was showed that a picornavirus IRES can hand
over components of the translation apparatus to another
translation start site on the same reporter RNA in cis. [51]. By
this translation enhancement such an internal picornavirus IRES
reduces possible effects of mutations or inhibitors of translation.
However, this study did not verify if the reduction of inhibition can
be observed when using cleaved mRNA (i.e. resulting from the
action of a ribozyme). Therefore, there is no certitude that the
camouflage phenomenon may have masked the action of some of
the tested SOFA-HDV ribozymes. Moreover, this possibility
cannot be evoked in order to explain the low level of cleavage
activity observed in cellulo for the collection of SOFA-HDV
ribozymes targeting the (2) strand. In that case it has to occur on
the opposite strand that is used for the translation.
Another potential explanation might be intrinsic to the SOFA-
HDV ribozymes or the fact that the ribozymes were linked to a
tRNA for their expression, which may impair their cleavage
ability. However, there is increasing evidence that the HCV viral
genome replicates in a peculiar membranous structure located
around the endoplasmic reticulum [52–54]. Electron microscopy
observations revealed that cells supporting the replication possess
an unusual membranous structure, and that part of the
endoplasmic reticulum membrane is notably deformed [44]. This
structure has a complicated shape, as well as a botryoidal structure
in some cases, and is also seen in liver specimen taken from HCV
infected patients. This structure was named a membranous web,
and is common to Flaviviridae. Both (+) and (2) HCV strands were
shown to be synthesized in a membrane-protected complex [44].
Moreover, HCV strands were shown to be resistant to micrococcal
nuclease treatment, a treatment that completely hydrolyzed
ribosomal RNA [44]. In contrast, HCV strands were fully
hydrolyzed by the nuclease treatment only when the experiment
was performed in the presence of a detergent which disrupted the
membraneous structures. Moreover, it has been shown that the
core recruits NS proteins, HCV RNAs and the replication
complex to lipid droplet-associated membranes. In fact, it has
been shown that lipid droplets play a central role in the production
of infectious HCV particles [44,45]. This situation considerably
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the SOFA-HDV ribozyme during replication, in agreement with
the limited inhibition observed for all of tested SOFA-HDV
ribozymes. Furthermore, this fact also explains why other nucleic
acid based approaches directed towards controlling the propaga-
tion of HCV, including antisense, ribozymes and deoxyribozymes
[19–22], and for which much effort has been devoted, has yielded
no commercial research program to date even though they
remains active. It has even been shown that the entire HCV (2)
strand was resistant to RNA interference [55]. These studies also
support the notion that the cellular localization of the HCV
strands significantly limits the possibility of controlling their
propagation by targeting the RNA directly, certainly not the (2)
strand. In the case of siRNAs designed to target the HCV (+)
strands, the best of them achieved ,60% silencing [11–14].
Contrastly, one study did claim viral clearance based on siRNA
targeting [15]. One possible explanation for the latest result may
be because siRNA take advantage on the cellular protein
machinery, which may have for effect to reduce the hurdle of
the HCV RNA strand accessibility. Altogether, this collection of
data suggests that much more work is required in order to achieve
development of a therapeutic approach directed against HCV,
including finding strategies that can release the viral strands from
their lipid droplets. At least, nucleic acid-based drugs should be
tested with an infection system in which the HCV RNA
accessibility problem could be overcome. Specifically, replicon
containing cells may already possess membranous alterations due
to replication complexes. Alternatively, the use of HCV-JFH1
virus cell culture system [41] may provide an open window of time
for targeting the HCV within the early stage of replication. When
initiating its infection, the viral RNA should be more exposed to
cellular translation system in order to produce viral proteins
required for RNA replication. At this point, HCV RNA strands
should be more available to our targeting component and the
resulting inhibition higher.
Materials and Methods
SOFA-HDV Ribozymes and DNA Constructs
SOFA-HDV ribozymes were constructed using a PCR-based
strategy that included two complementary and overlapping oligonu-
cleotides as described previously [ 2 9 ] .B r i e f l y ,t w oD N Ao l i g o n u c l e -
otides were used: the universal reverse primer (59-CCAGCTA-
GAAAGGGTCCCTTAGCCATCCGCGAACGGATGCCC-39)
and the SOFA-HDV ribozyme sense primer (59-TAATACGACT-
CACTATAGGGCCAGCTAGTTT(N)11–12BS(N)4BLCAGGGTC-
CACCTCCTCGCGGT(N)
6P1TGGGCATCCGTTCGCGG-39),
where N represents A, C, G or T and BS, BL and P1 indicate the
biosensor, the blocker sequence and the P1 recognition domain,
respectively. The SOFA-HDV ribozyme sense primer is specific for
each ribozyme and permits the incorporation of the T7 RNA
promoter, while the universal antisense primer was used with all
ribozymes. The 59 to 39 elongation of the DNA sequence that
produced a double-stranded DNA template was performed using Pwo
DNA polymerase (Roche Diagnostics). The PCR products were
ethanol precipitated, dissolved in water and were then used either for
in vitro transcription (see below) or in a second PCR reaction (for
cloning purposes). The tRNA
Val:SOFA-HDV ribozyme chimeric
constructs were generated as described previously [26]. Briefly, the
first PCR products were used as templates in order to produce a
double-stranded DNA sequence containing a KpnI restriction site in
59. For this second PCR, the universal reverse primer was used in
combination with a universal SOFA KpnI forward primer (59-
CGGGGTACCGGGCCAGCTAGTTT-39) in a filling reaction
using Pwo DNA polymerase. This PCR product was ethanol-
precipitated prior to digestion with KpnI (New England Biolabs). The
digested amplicons were ligated to KpnI/EcoRV co-digested
ptRNA
Val vector derived from pcDNA3.1 (Invitrogen) as described
previously [26]. The resulting constructions produce tRNA
Val-driven
SOFA-HDV ribozymes targeting various regions of either the HCV
59 UTR or its complementary sequence in the (2)s t r a n d .I no r d e rt o
construct lentiviral vectors for each ribozyme, the entire tRNA
Val:-
SOFA-HDV ribozyme was amplified by PCR using purified Pwo
DNA polymerase and a tRNA-EcoRI forward primer (59-TATT-
GAATTCACCGTTGGTTTCCGTAG-39) coupled with a SOFA-
Rz-XhoI reverse primer (59-ATAACTCGAGAAAAAAGATC-
CAGCTAGAAAGGG-39). EcoRI-XhoI co-digested PCR products
and pLentiV5-U6 (Invitrogen) were ligated together, producing a
lentiviral vector that expresses the tRNA
Val:SOFA-HDV ribozyme
(the co-digestion of pLentiV5-U6 removes the U6 promoter). All
constructions were verified by DNA sequencing.
Plasmid pHCVA was constructed by cloning the 1348-nt HCV
59 sequence from pHCV-1b [56] into the HindIII/BamHI sites of
pcDNA3 (Invitrogen). Plasmid pHCV(2) was constructed by
subcloning the HindIII/KpnI restriction fragment of pHCVA into
pcDNA3.1(2) (Invitrogen).
RNA Synthesis by In Vitro Transcription
B o t ht h er i b o z y m ea n dt h eH C V - d e r i v e dt r a n s c r i p t sw e r e
synthesized by run-off transcription as described previously [29].
Briefly, transcriptions were performed in the presence of purified T7
RNA polymerase (10 mg), RNAGuard (24 U, GE Healthcare),
pyrophosphatase (0.01 U, Roche Diagnostics) and either KpnI-
linearized pHCVA (5 mg), HindIII-linearized pHCV(2)( 5mg) or
P C Rp r o d u c t( 2t o5mM) in a buffer containing 80 mM HEPES-
KOH, pH 7.5, 24 mM MgCl2, 2 mM spermidine, 40 mM DTT
and 5 mM of each NTP in a final volume of 100 mLa t3 7 uCf o r2h .
Upon completion, the reaction mixtures were treated with DNase
RQ1 (Promega) at 37uC for 20 min, and the RNA then purified by
phenol:chloroform extraction and ethanol precipitation. The result-
ing pellets were dissolved in equal volumes of ultrapure water and
loading buffer (95% formamide, 10 mM EDTA, pH 8.0, 0.025%
xylene cyanol and 0.025% bromophenol blue). The samples were
then fractionated through either 5% or 8% denaturing polyacryl-
amide gels (PAGE, 19:1 ratio of acrylamide to bisacrylamide) in
buffer containing 45 mM Tris-borate, pH 7.5, 8 M urea, and 2 mM
EDTA. The reaction products were visualized by ultraviolet (UV)
shadowing. The bands corresponding to the correct sizes for both the
ribozymes and the HCV-derived RNAs were cut out and the
transcripts eluted overnight at room temperature in elution buffer
(500 mM ammonium acetate, 10 mM EDTA, 0.1% SDS). The
transcripts were ethanol precipitated, washed, dried and dissolved in
ultrapure water. The RNA was quantified by absorbance at 260 nm.
RNA Substrate Labeling
In order to generate 59-end-labeled RNA substrate, 50 pmol of
purified transcripts were dephosphorylated by adding 1 U of
Antartic phosphatase (New England Biolabs) and incubating for
1 h at 37uC in a final volume of 10 mL containing 50 mM Bis-
Propane, pH 6.0, 1 mM MgCl2, 0.1 mM ZnCl2 and 40 U of
RNAGuard. The enzyme was then inactivated by incubating at
65uC for 8 min. The dephosphorylated RNAs (5 pmol) were then
59-end labeled by incubation for 1 h at 37uC with 3 U of T4
polynucleotide kinase (USB) and 3.2 pmol of [c-
32P]ATP
(6000 Ci/mmol; New England Nuclear) in the provided reaction
buffer. The reactions were stopped by the addition of two volumes
of loading buffer. The 59-end-labeled RNA substrates were
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autoradiography, cut out and eluted as described above.
Determination of the Most Accessible Sites within the
HCV RNA
The selection of potential target sites was performed as
previously described [33]. Briefly, the bioinformatic approach
includes three steps. First, the RNA Structure 3.7 software was
used to both fold the HCV RNA and to predict the most stable
secondary structure of the first 341 nucleotides, in terms of energy,
of the genotype 1b variant (NCBI database accession number:
AJ238799). Secondly, using the OligoWalk software [34], the
accessibility for the binding of complementary 7-mer oligonucle-
otides mimicking the HDV Rz binding domain was assessed in
silico on the predicted structures. Thirdly, the accessibility of the
resulting sites in vitro was verified by ribonuclease H probing. The
reactions were performed using 59-end-labeled HCV-derived 575-
nt transcripts (,0.1 mM, ,50,000 CPM) in combination with 7-
mer oligonucleotides (5 mM) complementary to a specific sequence
on the substrate. Each oligonucleotide was used in the presence of
the substrate, and was pre-incubated for 10 min at 25uC in a final
volume of 8 mL containing 20 mM Tris-HCL, pH 7.5, 20 mM
KCl, 10 mM MgCl2, 0.1 mM EDTA and 0.1 mM DTT. RNase
H (0.5 units, Ambion) was then added (2 mL) and the samples were
incubated at 37uC for 30 min. The reactions were quenched by
the addition of one volume of loading buffer, loaded on denaturing
5–10% PAGE gels and, after electrophoresis exposed to
PhosphorImager screens (Storm apparatus, Molecular Dynamics).
In Vitro Ribozyme Cleavage Assays
The conditions for SOFA–HDV ribozyme cleavage assays have
been described previously [29]. Briefly, 59-end-labeled 575-nt HCV-
derived transcripts of 575 nt (,50,000 CPM) were mixed with
SOFA-HDV Rz (10 pmol) in a 20 mL reaction containing 50 mM
Tris-HCl, pH 7.5 and 10 mM MgCl2, and were then incubated at
37uC for 3 h. The reactions were stopped by the addition of one
volume of loading buffer, fractionated on denaturing 5–8% PAGE
gels which were then exposed to PhosphorImager screens.
Lentivirus Production, Cell Culture and In Cellulo Assays
Lentivirus were produced as described previously [57]. Briefly,
5610
6 HEK 293-FT cells were seeded in 100 mm tissue culture
dishes. The next day, the media was replaced by Opti-MEM
(Gibco-BRL) media prior to transfection of 6 mg each of pLenti
tRNA
Val:SOFA Rz, pLP1, pLP2 and pLP/VSVG (Invitrogen)
with Lipofectamine 2000 (Invitrogen). After a 4 h incubation, the
Opti-MEM was changed for DMEM containing 10% FBS. At
72 h post-transfection, the viral supernatant was filtered through a
0.45 mm Millipore filter. Each viral stock was titrated by counting
the number of CFU produced by transduction of HT1080 cells
with different dilutions of the viral stock.
Huh-7 cells containing the subgenomic biscistronic replicon
Luc-ubi-neo-ET (kindly provided by R. Bartenschlager [37]) were
cultured in 100 mm cell culture dishes in Dulbecco’s Modified
Eagle Medium (DMEM, Wisent) supplemented with 10% FBS
(Wisent), 1 mM sodium pyruvate, 2 mM L-glutamine, 250 mg/
mL G-418 (Wisent). The cells were passaged twice weekly at a
dilution of 1:4-1:8 depending on the rate of cell growth. Prior to
transduction, Huh-7 cells containing the bicistronic replicon were
seeded in 24 well plates at a confluence of 5610
4 cells per well.
From that point and until the end of the experiment, Huh-7 cells
containing the replicon were never in contact with media
containing G-418 or antibiotic. The next day, the media was
replaced by 250 mL of filtered lentivirus stock (MOI&1)
containing 6 mg/mL hexadimethrine bromide (polybrene, Sigma
Aldrich) and the plates then incubated at 37uC for 48 h.
The dual-luciferase reporter assay system (Promega) was used in
order to monitor the firefly luciferase as reported elsewhere [58].
Briefly, the cells were washed with 1X PBS and then were lysed in
150 mL of Passive Lysis Buffer for 20 min at room temperature.
The luciferase activity was measured by the addition of 20 mLo f
lysate to 100 mL of luciferase assay reagent II (Promega) in a 5 mL
test tube followed by reading on a Berthold Lumat LB9501
luminometer (Berthold Technologies). For each lysate, the total
protein concentration was determined using the Bradford assay
(Bio-Rad). Data was expressed as a ratio of RLU per mg of total
protein, and was then normalized for each ribozyme by dividing
by the result obtained with a control ribozyme (i.e. SOFA-HDV-
RzHBV). Both the mean value and the standard deviation were
calculated for each ribozyme.
Acknowledgments
The authors would like to thank R. Bartenschlager for kindly providing the
bicistronic HCV replicon.
Author Contributions
Conceived and designed the experiments: MVL JPP. Performed the
experiments: MVL DL FPB. Analyzed the data: MVL JPP. Wrote the
paper: MVL JPP.
References
1. Moradpour D, Brass V, Gosert R, Wo ¨lk B, Blum HE (2002) Hepatitis
C: molecular virology and antiviral targets. Trends Mol Med 8: 476–
482.
2. Chisari FV (2005) Unscrambling hepatitis C virus-host interactions. Nature 436:
930–932.
3. Griffiths J, Nix B (2002) Modeling the hepatitis C virus epidemic in France using
the temporal pattern of hepatocellular carcinoma deaths. Hepatology 35:
709–715.
4. Lindenbach BD, Rice CM (2005) Unravelling hepatitis C virus replication from
genome to function. Nature 436: 933–938.
5. Spahn CM, Kieft JS, Grassucci RA, Penczek PA, Zhou K, et al. (2001) Hepatitis
C virus IRES RNA-induced changes in the conformation of the 40S ribosomal
subunit. Science 291: 1959–1962.
6. De Francesco R, Migliaccio G (2005) Challenges and successes in developing
new therapies for hepatitis C. Nature 436: 953–960.
7. Pereira AA, Jacobson IM (2009) New and experimental therapies for HCV. Nat
Rev Gastroenterol Hepatol 6: 403–411.
8. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, et al. (2003) An NS3
protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Nature 426: 186–189.
9. Beaulieu PL, Tsantrizos YS (2004) Inhibitors of the HCV NS5B polymerase:
new hope for the treatment of hepatitis C infections. Curr Opin Investig Drugs
5: 838–850.
10. Olsen DB, Eldrup AB, Bartholomew L, Bhat B, Bosserman MR, et al. (2004) A
7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus
replication with excellent pharmacokinetic properties. Antimicrob Agents
Chemother 48: 3944–3953.
11. Kro ¨nke J, Kittler R, Buchholz F, Windisch MP, Pietschmann T, et al. (2004)
Alternative approaches for efficient inhibition of hepatitis C virus RNA
replication by small interfering RNAs. J Virol 78: 3436–3446.
12. Kapadia SB, Brideau-Andersen A, Chisari FV (2003) Interference of hepatitis C
virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 100:
2014–2018.
13. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, et al. (2003)
Inhibition of intracellular hepatitis C virus replication by synthetic and vector-
derived small interfering RNAs. EMBO Rep 4: 602–608.
14. Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue-Gervais IG, et al.
(2003) RNA interference blocks gene expression and RNA synthesis from
hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci USA
100: 2783–2788.
Ribozyme Targeting HCV
PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e962715. Randall G, Grakoui A, Rice CM (2003) Clearance of replicating hepatitis C
virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad
Sci USA 100: 235–240.
16. Marques JT, Williams BR (2005) Activation of the mammalian immune system
by siRNAs. Nat Biotechnol 23: 1399–1405.
17. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation
of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834–839.
18. Kim DH, Longo M, Han Y, Lundberg P, Cantin E, et al. (2004) Interferon
induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat
Biotechnol 22: 321–325.
19. Welch PJ, Tritz R, Yei S, Leavitt M, Yu M, et al. (1996) A potential therapeutic
application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for
hepatitis C virus infection. Gene Ther 3: 994–1001.
20. Trepanier J, Tanner JE, Momparler RL, Le ON, Alvarez F, et al. (2006)
Cleavage of intracellular hepatitis C RNA in the virus core protein coding region
by deoxyribozymes. J Viral Hepat 13: 131–138.
21. Ohkawa K, Yuki N, Kanazawa Y, Ueda K, Mita E, et al. (1997) Cleavage of
viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific
hammerhead ribozyme in vitro. J Hepatol 27: 78–84.
22. Macejak DG, Jensen KL, Jamison SF, Domenico K, Roberts EC, et al. (2003)
Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and
replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.
Hepatology 31: 769–776.
23. Le ´vesque D, Choufani S, Perreault JP (2002) Delta ribozyme benefits from a
good stability in vitro that becomes outstanding in vivo. RNA 8: 464–477.
24. Asif-Ullah M, Le ´vesque M, Robichaud G, Perreault JP (2007) Development of
ribozyme-based gene-inactivations; the example of the hepatitis delta virus
ribozyme. Curr Gene Ther 7: 205–216.
25. Fiola K, Perreault JP, Cousineau B (2006) Gene targeting in the gram-positive
bacterium Lactococcus lactis, using various delta ribozymes. Appl Environ
Microbiol 72: 869–879.
26. D’Anjou F, Bergeron LJ, Larbi NB, Fournier I, Salzet M, et al. (2004) Silencing
of SPC2 expression using an engineered delta ribozyme in the mouse betaTC-3
endocrine cell line. J Biol Chem 279: 14232–14239.
27. Al-Anouti F, Ananvoranich S (2002) Comparative analysis of antisense RNA,
double-stranded RNA, and delta ribozyme-mediated gene regulation in
Toxoplasma gondii. Antisense Nucleic Acid Drug Dev 12: 275–281.
28. Robichaud GA, Perreault JP, Ouellette RJ (2008) Development of an isoform-
specific gene suppression system: the study of the human Pax-5B transcriptional
element. Nucleic Acids Res 36: 4609–4620.
29. Bergeron LJ, Perreault JP (2005) Target-dependent on/off switch increases
ribozyme fidelity. Nucleic Acids Res 33: 1240–1248.
30. Bergeron LJ, Reymond C, Perreault JP (2005) Functional characterization of the
SOFA delta ribozyme. RNA 11: 1858–1868.
31. Fong TL, Shindo M, Feinstone SM, Hoofnagle JH, Di Bisceglie AM (1991)
Detection of replicative intermediates of hepatitis C viral RNA in liver and
serum of patients with chronic hepatitis C. J Clin Invest 88: 1058–1060.
32. Quinkert D, Bartenschlager R, Lohmann V (2005) Quantitative analysis of the
hepatitis C virus replication complex. J Virol 79: 13594–13605.
33. Bergeron LJ, Perreault JP (2002) Development and comparison of procedures
for the selection of delta ribozyme cleavage sites within the hepatitis B virus.
Nucleic Acids Res 30: 4682–4691.
34. Mathews DH, Burkard ME, Freier SM, Wyatt JR, Turner DH (1999) Predicting
oligonucleotide affinity to nucleic acid targets. RNA 5: 1458–1469.
35. Peracchi A (2004) Prospects for antiviral ribozymes and deoxyribozymes. Rev
Med Virol 14: 47–64.
36. Kato Y, Kuwabara T, Warashina M, Toda H, Taira K (2001) Relationships
between the activities in vitro and in vivo of various kinds of ribozyme and their
intracellular localization in mammalian cells. J Biol Chem 276: 15378–15385.
37. Bertrand E, Castanotto D, Zhou C, Carbonnelle C, Lee NS, et al. (1997) The
expression cassette determines the functional activity of ribozymes in
mammalian cells by controlling their intracellular localization. RNA 3: 75–88.
38. Vrolijk JM, Kaul A, Hansen BE, Lohmann V, Haagmans BL, et al. (2003) A
replicon-based bioassay for the measurement of interferons in patients with
chronic hepatitis C. J Virol Methods 110: 201–209.
39. Seo MY, Abrignami S, Houghton M, Han JH (2003) Small interfering RNA-
mediated inhibition of hepatitis C virus replication in the human hepatoma cell
line Huh-7. J Virol 77: 810–812.
40. Kroke J, Kittler R, Buchholz F, Windisch MP, Pietschmann T, et al. (2004)
Alternative approaches for efficient inhibition of hepatitis C vius RNA
replication by small interfering RNAs. J Virol 78: 3436–3446.
41. Sakamoto N, Tanabe Y, Yokota T, Satoh K, Sekine-Osajima Y, et al. (2008)
Inhibition of hepatitis C virus infection and expression in vitro and in vivo by
recombinant adenovirus expressing short hairpin RNA. Hepatology 23:
1437–1447.
42. Watanabe T, Umehara T, Yasui F, Nakagawa SI, Yano J, et al. (2007) Liver
target delivery of small interfering RNA to the HCV gene by lactosylated
cationic liposome. J Hepatol 47: 744–750.
43. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, et al. (2003)
Inhibition of intracellular hepatitis C virus replication by synthetic and vector-
derived small interfering RNAs. EMBO Reports 4: 602–608.
44. Egger D, Wo ¨lk B, Gosert R, Bianchi L, Blum HE, et al. (2002) Expression of
hepatitis C virus proteins induces distinct membrane alterations including a
candidate viral replication complex. J Virol 76: 5974–5984.
45. Miyanari Y, Hijikata M, Yamaji M, Hosaka M, Takahashi H, et al. (2003)
Hepatitis C virus non-structural proteins in the probable membranous
compartment function in viral genome replication. J Biol Chem 278:
50301–50308.
46. Smith RM, Walton CM, Wu CH, Wu GY (2002) Secondary structure and
hybridization accessibility of hepatitis C virus 39-terminal sequences. J Virol 76:
9563–9574.
47. Ananvoranich S, Lafontaine DA, Perreault JP (1999) Mutational analysis of the
antigenomic trans-acting delta ribozyme: the alterations of the middle
nucleotides located on the P1 stem. Nucleic Acids Res 27: 1473–1479.
48. Ananvoranich S, Perreault JP (1998) Substrate specificity of delta ribozyme
cleavage. J Biol Chem 273: 13182–13188.
49. Desche ˆnes P, Lafontaine DA, Charland S, Perreault JP (2000) Nucleotides 21t o
24 of hepatitis delta ribozyme substrate increase the specificity of ribozyme
cleavage. Antisense Nucleic Acid Drug Dev 10: 53–61.
50. Bergeron LJ, Ouellet J, Perreault JP (2003) Ribozyme-based gene-inactivation
systems require a fine comprehension of their substrate specificities: the case of
delta ribozyme. Curr Med Chem 10: 2589–2597.
51. Ju ¨nemann C, Song Y, Bassili G, Goergen D, Henke J, et al. (2007) Picornavirus
internal ribosome entry site elements can stimulate translation of upstream
genes. J Biol Chem 282: 132–141.
52. Ogawa K, Hishiki T, Shimizu Y, Funami K, Sugiyama K, et al. (2009) Hepatitis
C virus utilizes lipid droplet for production of infectious virus. Proc Jpn Acad
Ser B Phys Biol Sci 85: 217–228.
53. McLauchlan J (2009) Hepatitis C virus: viral proteins on the move. Biochem Soc
Trans 37: 986–990.
54. Miller S, Krijnse-Locker J (2008) Modification of intracellular membrane
structures for virus replication. Nat Rev Microbiol 6: 363–374.
55. Smith RM, Smolic R, Volarevic M, Wu GY (2007) Positional effects and strand
preference of RNA interference against hepatitis C virus target sequences. J Viral
Hepat 14: 194–212.
56. Hicham Alaoui-Ismaili M, Gervais C, Brunette S, Gouin G, Hamel M, et al.
(2000) A novel high throughput screening assay for HCV NS3 helicase activity.
Antiviral Res 46: 181–193.
57. Boudreau F, Lussier CR, Mongrain S, Darsigny M, Drouin JL, et al. (2007) Loss
of cathepsin L activity promotes claudin-1 overexpression and intestinal
neoplasia. FASEB J 21: 3853–3865.
58. Liu Q, Fu H, Sun F, Zhang H, Tie Y, et al. (2008) miR-16 family induces cell
cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 36:
5391–5404.
Ribozyme Targeting HCV
PLoS ONE | www.plosone.org 11 March 2010 | Volume 5 | Issue 3 | e9627